Voren

Main information

  • Trade name:
  • Voren Enteric Microencapsulated Capsule
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Voren Enteric Microencapsulated Capsule
    Malaysia
  • Language:
  • English

Other information

Status

  • Source:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Authorization number:
  • MAL19987985
  • Last update:
  • 28-05-2018

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

VOREN ENTERIC MICROENCAPSULATED CAPSULE

Diclofenac sodium (50mg)

1

Consumer Medication Information Leaflet (RiMUP)

What is in this leaflet

What VOREN is used for

How VOREN works

Before you use VOREN

How to use VOREN

While you are using it

Side effects

Storage and Disposal of VOREN

Product Description

Manufacturer and Product

Registration Holder

Date of revision

What VOREN

is used for

It is used for:

Inflammatory and degenerative forms

of rheumatism

Rheumatoid

arthritis

(systemic

inflammatory disorder that affects

joints)

Ankylosing

spondylitis

(chronic

inflammatory

disease

skeleton)

Osteoarthritis

(degenerative

joint

disease)

Spondylarthritis

(inflammation

the joint)

Non-articular

rheumatism

(musculoskeletal

aches

pains

which do not arise from joints).

Post

traumatic

inflammation

swelling.

How VOREN works

VOREN

contains

substance

called

Diclofenac.

belongs

group

medicines

called

non-steroidal

anti-

inflammatory

agents

(NSAIDs)

which

reduces fever, pain and inflammation.

VOREN

enteric

coated

tablet

allow

medication to be distributed on a larger

surface area which can reduce the risk of

damage caused by the dumping of the

medication

area.

Moreover,

VOREN enteric-coated can also achieve

more

stable

plasma

concentration,

releases

medication

more

slowly,

providing

better

dosage

accuracy

increased bioavaibility.

Before you use VOREN

When you must not use it

Do not use VOREN:

If you are aspirin-sensitive.

If you have active stomach ulcer or

stomach and intestinal bleeding.

have

allergy

hypersensitivity

Diclofenac,

other

NSAIDs

other

ingredients listed at the end of this

leaflet

Before you start to use it

Tell your doctor or pharmacist:

If you have heart disease or stroke

If you have high blood pressure

Diclofenac may cause severe skin

reactions,

e.g.

toxic

epidermal

necrolysis,

Steven-Johnson

Sydrome.

Symptoms

may include

skin

rash,

blisters

peel

off.

These could be signs of a serious

condition. If these reactions occur,

stop

seek

medical

assistance right away.

If you have or have had ulceration,

bleeding

perforation

stomach and intestinal

suffering

from

dyspepsia

(discomfort at the epigastric region

due to digestion problem).

If you have bleeding disorder

have

kidney

liver

problem

If you are concomitantly administer

anti-inflammatory

drugs

other

non-steroidal

anti-inflammatory

drugs

including

aspirin

(blood

thinning agent)

If you have fluid retention or heart

failure.

If you have infection.

Please consult your doctor before

start

VOREN

pregnant, plan to become pregnant,

breast-feeding or intend to breast-

feed.

Your

doctor

will

have

weighed

risks

taking

VOREN against the benefits they

expect it will have for you.

Taking other medicines

Tell your doctor if you are taking any

other

medicines,

including

that

you buy without a prescription from a

pharmacy, supermarket or health food

shop.

Some

medicines

when

taken

with

VOREN may interfere with each other.

These include:

Potassium-sparing diuretics, water

pills

Aspirin, for blood thinning

Warfarin, medicine to prevent

blood clot

Digoxin, medicine for heart

Methotrexate, a medicine used to

treat rheumatoid arthritis, as well as

some types of cancers

Cyclosporin

medicine

used

after

organ transplant

7.

Oral hypoglycemics, for diabetes

How to use VOREN

How much to use

Adult: 1 capsule twice daily

Please follow the instruction given by

your doctor. Your doctor might want

to prescribe you the lowest effective

dose for the shortest duration.

When to use it

Use as directed by your doctor or

pharmacist.

How long to use it

Continue taking VOREN

for as long as

your doctor recommends.

If you forget to use it

If you miss a dose of VOREN, take it

as soon as possible. If it is approaching

time for the next dose, skip the missed

dose

back

your

regular

dosing schedule. Do not double doses.

If you use too much (overdose)

Contact your doctor immediately or go

to the Emergency Department of your

nearest hospital, if you think you or

anyone else may have taken too much

of this medicine. Do this even if there

signs

discomfort

poisoning.

need

urgent

medical attention.

Taking

many tablets

may cause

stomach

intestinal,

kidney,

brain toxicities, stomach and intestinal

bleeding,

kidney

failure,

convulsion

and coma.

While you are using it

Things you must do

Take your medicine exactly as your

doctor has told you.

2

Consumer Medication Information Leaflet (RiMUP)

Tell

doctors,

dentists

pharmacists treating you that you are

taking VOREN.

Tell your doctor immediately if you

become

pregnant

while

taking

this

medication

.

Things you must not do

Do not stop taking the medicine unless

advised by your doctor.

take

medicines

without consulting your doctor.

Do not give VOREN

to anyone else,

even if they have the same symptoms

or condition as you.

Things to be careful of

careful

driving

operating

machinery

until

know

VOREN affects you

Side effects

Stomach and intestinal side effects are

common.

Other side effects are:

Central

nervous

system:

Headache,

insomnia,

somnolence

(sleepiness)

and dizziness

Kidney

toxicity,

edema

(swelling),

palpitation

(feel

your

heart

beat),

minor

hearing

disorders,

blood

disorder

(Thrombocytopenia

eosinophilia).

- Skin disorder: rashes or skin eruptions

- Cases of hair loss, bullous eruption,

erythema

multiforme,

Stevens

Johnson

syndrome,

toxic

epidermal

necrolysis

(Lyell’s

syndrome),

photosensitivity reactions have been

reported.

Like all medicines, VOREN can cause

side effects, although not everybody gets

them.

Visit

your

doctor

pharmacist

immediately if you experience any side

effects after taking this medicine.

report

side

effects

adverse

drug

reactions

directly

National

Centre

Adverse

Drug

Reaction Monitoring by calling Tel: 03-

78835550,

visiting

website

portal.bpfk.gov.my

(Consumers

Reporting).

Storage and Disposal of VOREN

Storage

Keep in a tight container. Store below

30 °C, protect from light and moisture.

Disposal

Medicines should not be disposed of

wastewater

household

waste.

Ask your pharmacist how to dispose of

medicines no longer required. These

measures

will

help

protect

environment.

Product Description

What it looks like

hard

gelatin

transparent

body

containing

milky-

white pellets.

Ingredients

Active ingredient:

Diclofenac sodium

MAL number:

MAL19987985A

Manufacturer & Product Registration

Holder

Y.S.P. Industries (M) Sdn. Bhd.

&

Jalan

P/7,

Section

Kawasan

Perindustrian

Bandar

Baru

Bangi,

43000

Kajang,

Selangor

D.E.,

Malaysia.

Date of revision

28/12/2015

Serial Number:

BPFK(R4/1)101215/00489

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of polyacrylic acid, sodium salt, cross‐linked, FCM substance No 1015, which is intended to be used as a liquid absorber in the packaging of fresh or frozen foods such as meat, poultry and seafood as well as fresh fruits and vegetables. Specific migration tests were not performed due to the high absorption of liquids by the substance. The Panel noted that if polya...

Europe - EFSA - European Food Safety Authority Publications

5-11-2018

Products containing metam-sodium: ANSES announces the withdrawal of marketing authorisations

Products containing metam-sodium: ANSES announces the withdrawal of marketing authorisations

Plant protection products containing metam-sodium are used in market gardening and horticulture to disinfect the soil. Following the substance's approval at European level, ANSES reassessed the dossiers and notified the industrial companies concerned of its intention to withdraw all marketing authorisations for metam-sodium products. ANSES is also taking this opportunity to reiterate the importance of phytopharmacovigilance and the requirement for professionals to report any adverse effects on humans or ...

France - Agence Nationale du Médicament Vétérinaire

18-9-2018

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Published on: Fri, 14 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Austria for the pesticide active substance sodium hydrogen carbonate are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative use of sodium hyd...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

31-8-2018

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA is warning the public about a voluntary recall of one lot of montelukast sodium tablets made by Camber Pharmaceuticals due to incorrect drug in bottles

FDA - U.S. Food and Drug Administration

29-8-2018

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.

FDA - U.S. Food and Drug Administration

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

11-7-2018

MyNicNaxs, LLC Issues Voluntary Nationwide Recall of Various Dietary Supplements Due to Undeclared Active Pharmaceutical Ingredient (API)

MyNicNaxs, LLC Issues Voluntary Nationwide Recall of Various Dietary Supplements Due to Undeclared Active Pharmaceutical Ingredient (API)

MyNicNaxs, LLC, Deltona, FL is voluntarily recalling all lots of dietary supplements distributed nationwide to the consumer level. The products have been found to contain undeclared active pharmaceutical ingredients (API). The presence of Sildenafil, Sibutramine, Diclofenac and/or Phenolphthalein in the dietary supplements renders it an unapproved drug for which safety and efficacy have not been established and, therefore, subject to recall. These products were distributed from January 2013, to December ...

FDA - U.S. Food and Drug Administration

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

28-11-2018

PHEBURANE (Eurocept International BV)

PHEBURANE (Eurocept International BV)

PHEBURANE (Active substance: Sodium Phenylbutyrate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8043 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2500/T/20

Europe -DG Health and Food Safety

26-9-2018

Kexxtone (Elanco GmbH)

Kexxtone (Elanco GmbH)

Kexxtone (Active substance: Monensin sodium) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6324 of Wed, 26 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2235/T/10

Europe -DG Health and Food Safety

24-9-2018

Inhixa (Techdow Europe AB)

Inhixa (Techdow Europe AB)

Inhixa (Active substance: enoxaparin sodium) - Centralised - Variation - Commission Decision (2018)6101 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4264/X/18, 26

Europe -DG Health and Food Safety

27-8-2018

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Active substance: Fondaparinux sodium) - PSUSA - Modification - Commission Decision (2018)5708 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/403/PSUSA/1467-201712

Europe -DG Health and Food Safety

3-8-2018

Sodium oxybate

Sodium oxybate

Sodium oxybate (Active substance: Sodium oxybate) - Centralised - Art 28 - (PSUR - Commission Decision (2018)5381 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10612/201710

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Active substance: Combination of carboplatin and sodium valproate) - Orphan designation - Commission Decision (2018)5275 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/036/18

Europe -DG Health and Food Safety

11-7-2018

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Active substance: Alendronate Sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4518 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/619/T/42

Europe -DG Health and Food Safety

10-7-2018

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Active substance: Alendronate sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4477 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/759/T/39

Europe -DG Health and Food Safety

10-7-2018

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Active substance: Sodium phenylbutyrate) - Centralised - Yearly update - Commission Decision (2018)4483 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Withdrawn application:  Prohippur, sodium benzoate, Initial authorisation

Withdrawn application: Prohippur, sodium benzoate, Initial authorisation

Europe - EMA - European Medicines Agency

19-6-2018

Xyrem (UCB Pharma S.A.)

Xyrem (UCB Pharma S.A.)

Xyrem (Active substance: Sodium oxybate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3912 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/593/T/74

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Active substance: Volanesorsen sodium) - Transfer of orphan designation - Commission Decision (2018)1822 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/082/16/T/01

Europe -DG Health and Food Safety